Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Analyst Ratings Changes
Separately, StockNews.com assumed coverage on Rockwell Medical in a report on Wednesday. They set a "hold" rating for the company.
Rockwell Medical Stock Performance
RMTI Stock opened at $2.06 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 5.21. The business's fifty day moving average price is $1.42 and its two-hundred day moving average price is $2.81. Rockwell Medical has a fifty-two week low of $1.17 and a fifty-two week high of $7.70.
Rockwell Medical (NASDAQ:RMTI - Get Rating) last posted its quarterly earnings data on Monday, August 15th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.25. Rockwell Medical had a negative return on equity of 474.88% and a negative net margin of 51.27%. During the same quarter in the previous year, the business posted ($0.99) EPS. As a group, analysts anticipate that Rockwell Medical will post -3.56 EPS for the current year.